Six observational studies were included in the analyses (n=393 patients).
In patients who had received cabergoline, there was a statistically significant increase in mild plus moderate tricuspid regurgitation (PR 1.40, 95% CI 1.17 to 1.67). No significant heterogeneity was found. The authors stated that none of the patients showed symptoms of cardiac valve disease.
There was no statistically significant increase associated with cabergoline in mild tricuspid regurgitation,or mitral or aortic valve regurgitation.